Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCC NYSEARCA:IWM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$2.12-6.0%$2.54$1.09▼$7.14$149.81M2.941.53 million shs1.34 million shsIWMiShares Russell 2000 ETF$243.77+2.5%$235.37$171.73▼$248.48$68.43B1.1533.69 million shs21.54 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics0.00%-0.88%-15.41%-5.46%-58.79%IWMiShares Russell 2000 ETF0.00%-3.27%-0.23%+6.54%+7.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$2.12-6.0%$2.54$1.09▼$7.14$149.81M2.941.53 million shs1.34 million shsIWMiShares Russell 2000 ETF$243.77+2.5%$235.37$171.73▼$248.48$68.43B1.1533.69 million shs21.54 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics0.00%-0.88%-15.41%-5.46%-58.79%IWMiShares Russell 2000 ETF0.00%-3.27%-0.23%+6.54%+7.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.43Hold$8.50301.89% UpsideIWMiShares Russell 2000 ETF 2.70Moderate Buy$243.61-0.07% DownsideCurrent Analyst Ratings BreakdownLatest CCCC and IWM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CCCCC4 TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CCCCC4 TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/23/2025CCCCC4 TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$5.00 ➝ $10.009/22/2025CCCCC4 TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $10.009/22/2025CCCCC4 TherapeuticsStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$6.009/17/2025CCCCC4 TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$8.009/16/2025CCCCC4 TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$8.009/15/2025CCCCC4 TherapeuticsStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$3.00 ➝ $6.009/3/2025CCCCC4 TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.009/3/2025CCCCC4 TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.00(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$35.58M4.23N/AN/A$3.06 per share0.69IWMiShares Russell 2000 ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$105.32M-$1.58N/AN/AN/A-325.88%-53.91%-33.26%10/30/2025 (Estimated)IWMiShares Russell 2000 ETFN/AN/A17.69∞N/AN/AN/AN/AN/ALatest CCCC and IWM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025CCCCC4 Therapeutics-$0.43N/AN/AN/AN/AN/A8/7/2025Q2 2025CCCCC4 Therapeutics-$0.38-$0.37+$0.01-$0.37$5.24 million$6.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/AIWMiShares Russell 2000 ETF$2.400.98%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A5.065.06IWMiShares Russell 2000 ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%IWMiShares Russell 2000 ETFN/AInsider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics8.73%IWMiShares Russell 2000 ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics15071.17 million64.96 millionOptionableIWMiShares Russell 2000 ETFN/A280.45 millionN/ANot OptionableCCCC and IWM HeadlinesRecent News About These CompaniesHere's to a Second $1 Trillion Year for ETFsOctober 10 at 8:49 AM | etftrends.comEGeorge Soros Just Bought These ETFsOctober 9, 2025 | 247wallst.comThis ETF Weeds Out Small-Cap Underperformers (IWM)...September 29, 2025 | marketbeat.comEven smaller tech stocks are getting expensive. But these sectors could be your next big win.September 27, 2025 | morningstar.comMHow Much of a Stock Correction Should Investors Expect?September 26, 2025 | seeitmarket.comS4 Reasons for Q4 to Start on a Strong Note: ETFs to PlaySeptember 26, 2025 | zacks.comSell Weekly IWM Put Options = NEVER. WORK. AGAIN.September 24, 2025 | msn.comA Small-Stock Index Recently Set a New Record. What's Next for Small Caps?September 19, 2025 | msn.comStocks Hit All-Time Highs as Small-Caps Stage BreakoutSeptember 19, 2025 | zacks.comShould iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?September 19, 2025 | zacks.comETF Daily Flows: U.S. Equity Sees Outflows While International and Fixed Income GainSeptember 16, 2025 | finance.yahoo.comWall Street Soars To Records On Fed Rate Bets: What's Moving Markets Thursday?September 11, 2025 | aol.comAiShares Russell 2000 ETF (IWM) – Elliott Wave buying the dips at the blue boxSeptember 5, 2025 | fxstreet.comWill Small-Cap ETFs be Able to Sustain the New-Found Optimism?September 4, 2025 | zacks.comTNA: Benefits And Risks Of A Leveraged Small Cap ETFSeptember 3, 2025 | seekingalpha.comSmall-Cap ETFs: It's Not Just About the Russell 2000August 29, 2025 | etftrends.comEAfter Years of Pain, Riskiest Stocks Finally See Some MomentumAugust 28, 2025 | fa-mag.comFChart Of The Day: The Smaller They Are, The Harder They RallyAugust 27, 2025 | seekingalpha.comETFs to Ride the Small-Cap Comeback WaveAugust 27, 2025 | zacks.comThe 'Everything Rally' Is Back—Thanks To Powell's Risky Bet On JobsAugust 25, 2025 | msn.comTop 5 ETFs and Stocks to Watch as the Fed Eyes Rate Cuts (IWM)...August 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCCC and IWM Company DescriptionsC4 Therapeutics NASDAQ:CCCC$2.12 -0.14 (-6.00%) As of 01:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.iShares Russell 2000 ETF NYSEARCA:IWM$243.77 +5.98 (+2.52%) As of 01:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.iShares Russell 2000 ETF (the Fund) is an exchange-traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Russell 2000 Index (the Index). The Index is a float-adjusted capitalization weighted index that measures the performance of the small-capitalization sector of the United States equity market and includes securities issued by the approximately 2,000 smallest issuers in the Russell 3000 Index. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Index is a subset of the Russell 3000 Index, and serves as the underlying index for the Russell 2000 Growth and Value Index series. Component companies are adjusted for available float and must meet objective criteria for inclusion to the Index. The Fund's investment adviser is BlackRock Fund Advisors (BFA). More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Microsoft 365 Premium Marks the Next Phase of AI Monetization 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
